G-protein-coupled receptor kinase: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>David E. Volk m (subpages and meta) |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[biochemistry]] and [[signal transduction]], '''G-protein-coupled receptor kinases''' are a "family of serine-threonine kinases that are specific for [[G-protein-coupled receptor]]s. They are regulatory proteins that play a role in [[G-protein-coupled receptor]] densensitization."<ref>{{MeSH}}</ref> | In [[biochemistry]] and [[signal transduction]], '''G-protein-coupled receptor kinases''' are a "family of serine-threonine kinases that are specific for [[G-protein-coupled receptor]]s. They are regulatory proteins that play a role in [[G-protein-coupled receptor]] densensitization."<ref>{{MeSH}}</ref> | ||
Revision as of 12:18, 8 March 2009
In biochemistry and signal transduction, G-protein-coupled receptor kinases are a "family of serine-threonine kinases that are specific for G-protein-coupled receptors. They are regulatory proteins that play a role in G-protein-coupled receptor densensitization."[1]
Pharmacogenomics
Regarding the treatment of heart failure, there is conflicting evidence whether beta-blockers medications are as effective in African-American patients as in Anglo patients.[2] This may be due to a polymorphism in African-American patients of the G protein–coupled cell surface receptor kinase (GRK5) (OMIM) that confers a natural "genetic beta-blockade".[3]
References
- ↑ Anonymous (2024), G-protein-coupled receptor kinase (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Shekelle PG, Rich MW, Morton SC, et al (2003). "Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials". J. Am. Coll. Cardiol. 41 (9): 1529–38. PMID 12742294. [e]
- ↑ Liggett, Stephen B et al. 2008. A GRK5 polymorphism that inhibits [beta]-adrenergic receptor signaling is protective in heart failure. Nat Med advanced online publication. http://dx.doi.org/10.1038/nm1750 (Accessed April 29, 2008).